Perhaps I could speak to the second question regarding accessibility and the cross-border issues in Canada.
Our common drug review, for example, was a program that was set up by the provinces and territories and the drug programs within the federal government. They created it about 10 years ago because of that issue. They were all dealing with their own processes and all looking at the information in a slightly different way. The common drug review has balanced that information. We do that assessment on behalf of all of the provinces and territories, except Quebec, and produce a recommendation that informs their decision-making. Our statistics show that about 92% of the time when they make a decision, it's consistent with a recommendation we put forward.